Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Grassley Unsatisfied With FDA Commissioner-Nominee Von Eschenbach

This article was originally published in The Gray Sheet

Executive Summary

Sen. Chuck Grassley (R-Iowa) signaled Nov. 30 he is not ready to back down from strong reservations about confirming FDA Acting Commissioner Andrew von Eschenbach to the permanent post after receiving the nominee's 1responses to 15 questions

You may also be interested in...



Von Eschenbach Clears Senate Handily After Months Of Debate

Andrew von Eschenbach can officially take the helm of FDA, following confirmation by the Senate Dec. 7

Von Eschenbach Clears Senate Handily After Months Of Debate

Andrew von Eschenbach can officially take the helm of FDA, following confirmation by the Senate Dec. 7

Advisory Panel Conflict Waivers To Stay; FDA Will Provide Clarity On Process

FDA's plan for improving its advisory committee member selection process focuses on increasing the transparency and consistency of the existing process rather than a more extensive overhaul

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel